References
- Biogen Idec Inc., and Genentech Inc., Rituxan® (Rituximab). South San Francisco, CA Biogen Idec Inc., and Genentech, Inc. Prescribing information, 2007. www.rituxan.com
- WHO (World Health Organization) Toxicity Criteria by Grade. http://www.fda.gov/cder/cancer/toxicityframe.htm
- Pamuk G E, Donmez S, Turgut B, Demir M, Vural O. Rituximab-induced acute thrombocytopenia in a patient with prolymphocytic leukemia. Am J Hematol 2005; 78: 81
- Shah C, Grethlein S J. Case report of rituximab-induced thrombocytopenia. Am J Hematol 2004; 75: 263
- Otrock Z K, Mahfouz R A, Oghlakian G O, Salem Z M, Bazarbachi A. Rituximab-induced acute thrombocytopenia: a report of two cases. Haematologica 2005; 90: 7–8
- Larrar S, Guitton C, Willems M, Bader-Meunier B. Severe hematological side effects following Rituximab therapy in children. Haematologica 2006; 91: 11–12